Repligen Appoints Olivier Loeillot as President and Chief Commercial Officer
02 Octubre 2023 - 6:30AM
Repligen Corporation (NASDAQ:RGEN), a life sciences company focused
on bioprocessing technology leadership, today announced that it has
appointed 20+ year industry veteran Olivier Loeillot to the newly
created position of President and Chief Commercial Officer (CCO),
effective immediately. Mr. Loeillot served a combined 12 years with
Cytiva (a Danaher company) and GE Healthcare Life Sciences. In his
most recent role at Cytiva, he served as Bioprocess President from
2018 to 2022, overseeing the overall Bioprocess portfolio from cell
culture media to purification resins and including process
equipment, single-use technologies and enterprise solutions. Prior
to Cytiva, he worked for a combined 12 years with Lonza, advancing
to Vice President Sales, Lonza Custom Manufacturing. Mr. Loeillot
joins Repligen from his most recent role as Chief Executive Officer
(CEO) of Ascensus Specialties, a manufacturer of specialty
chemicals for use in the life sciences and pharmaceutical markets.
At Repligen, Mr. Loeillot will oversee all business units as
well as the commercial organization, driving the commercial and
corporate key account strategy and expanding the market impact of
Repligen’s business units in bioprocessing, while collaborating
with the company’s executive team in advancing the overall
bioprocess growth plan.
Tony J. Hunt, Chief Executive Officer at Repligen, said, “We are
delighted to welcome Olivier to our team at Repligen. His proven
management and leadership experience in global bioprocessing
markets strengthens our executive team and will enable us to reach
the next level of growth for the company, as we expand our market
footprint and execute on commercial and business strategies.”
Mr. Loeillot said, “I am excited to join Repligen, which has
quickly become the innovation leader in bioprocessing. I look
forward to applying my commercial and global business experience to
the company, working closely with Tony and the rest of the
executive team, to continue Repligen’s successful growth and to
advance Repligen to the next stage of its development.”
During his tenure at Cytiva, and prior to being named Bioprocess
President in 2018, Mr. Loeillot was instrumental in building and
leading the Enterprise Solutions business, managing the Bioprocess
ASIA business in Singapore, and directing the Genomics and Cellular
Research division. During his time at Lonza AG he served as Vice
President of Sales for the company’s Custom Manufacturing Business
(Basel) after leading the Microbial Biopharmaceuticals group
(Basel). Mr. Loeillot earned his Master’s degree in Chemistry in
1993 from the European High Institute of Chemistry (EHICS) of
Strasbourg, France, and later completed a Master’s of Business
Administration (MBA) program at CESMA Business School of EM
Lyon.
About Repligen CorporationRepligen Corporation
is a global life sciences company that develops and commercializes
highly innovative bioprocessing technologies and systems that
enable efficiencies in the process of manufacturing biological
drugs. We are “inspiring advances in bioprocessing” for the
customers we serve; primarily biopharmaceutical drug developers and
contract development and manufacturing organizations (CDMOs)
worldwide. Our focus areas are Filtration and Fluid Management,
Chromatography, Process Analytics and Proteins. Our corporate
headquarters are located in Waltham, Massachusetts, and the
majority of our manufacturing sites are in the U.S., with
additional key sites in Estonia, France, Germany, Ireland, the
Netherlands and Sweden. For more information about the our company
see our website at www.repligen.com, and follow us on LinkedIn.
This press release may contain forward-looking statements within
the meaning of the federal securities laws. Investors are cautioned
that statements in this press release which are not strictly
historical statements including, without limitation, statements
identified by words like “believe,” “expect,” “may,” “will,”
“should,” “seek,” or “could” and similar expressions, constitute
forward-looking statements. Such forward-looking statements are
subject to a number of risks and uncertainties that could cause
actual results to differ materially from those anticipated,
including risks discussed from time to time in our filings with the
Securities and Exchange Commission. We expressly disclaim any
responsibility to update any forward-looking statements, except as
required by law.
Repligen Contact: Sondra S. NewmanGlobal Head
of Investor Relations(781) 419-1881investors@repligen.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/1ef51b18-8283-4610-931f-d35f06779919
Repligen (NASDAQ:RGEN)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Repligen (NASDAQ:RGEN)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024